tailwind like continu ahead
reiter market outperform rate rais price target
follow releas result
state prior note achiev top-lin acceler organ cc
continu double-digit earn growth profil y/i eight consecut
quarter y/i rais sale guidanc mark third
consecut quarter increas annual expect feat uniqu fiscal
year driven solid growth within healthcar specialti servic life
scienc appli steril technolog ast busi well
modest gross oper margin improv bp bp y/i
quarterli revenu ep result beat consensu estim
respect out-performance first three quarter
compani fiscal year organ cc growth top-lin guidanc rais
organ cc previous y/i appear conserv opinion
believ potenti continu achiev substanti long-term
sale earn growth custom demand remain strong compani
product manag consist leverag top-lin improv
margin expans new price target base previous
new ep estim previous slight premium
group mid-to-high single-digit grow larg cap med-tech peer
total sale mln y/i cc organ top
consensu estim mln repres notabl beat
revenu driven increas volum bp price benefit
organ growth acquisit immateri therefor
includ organ sale compani revenu out-performance broad-
base double-digit organ cc increas life scienc ast
adjust ep y/i also top street expect driven
mostli sale out-performance modest y/i improv gross
oper margin bp bp respect gross margin
benefit favor product price mix somewhat off-set higher
labor cost oper margin expans bp achiev despit
increas higher compens expens increas cost
one fiscal quarter go manag rais top-lin guidanc
third consecut quarter organ cc previous y/i
currenc impact expect mln previous mln
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
currenc neutral organ growth first nine month compani full-
year expect impli lower organ growth rate sequenti harder
year-over-year compar versu howev given manag
comment regard continu demand across busi overal posit health
compani suspect bake conservat guidanc updat
compani reiter adjust ep guidanc comment full fiscal year
result come toward high-end y/i rang
turn segment perform healthcar product busi largest unit post sale
mln y/i organ cc driven strong consum revenu y/i
oper incom segment mln oper margin vs prior
year backlog decreas mln y/i mln prior quarter
healthcar specialti servic revenu mln y/i organ cc
double-digit growth repair continu contribut new outsourc reprocess
center come on-line oper profit mln om vs margin
impact start-up cost reprocess center personnel cost
appli steril ast sale mln organ cc repres
divis fourth consecut quarter top-lin growth acceler compani continu
see solid growth core medic devic custom ast oper incom mln
busi continu improv margin bp y/i
final life scienc revenu came mln y/i organ cc
increas capit equip sale despit strong shipment
number still finish quarter backlog record level
manag rais cc organ sale expect call y/i previous
y/i top-lin growth adjust ep expect reiter call rang
manag expect result come toward high end rang
increas due out-performance underli businessnow expect come high end rang plc
figur outlin actual result vs jmp estim rang revenu metric along
bpshealthcar specialti bpslife bpsappli steril bpstotal mln annual bpscog bpsgross bpsup bp y/i favor impact improv product price mix somewhat off-set higher labor bpsoper profit bpsup bp y/i despit increas expens relat higher compens tax bpsnet incom ex mix cc organ y/i consum benefit new product recent acquir busi servic capit equip capit equip backlog decreas mln y/i mln previou quarter segment oper incom mln om vs mix y/i cc organ y/i driven double-digit growth repair busi contribut new outsourc reprocess center come on-line oper incom segment mln om vs y/i higher revenu off-set invest made add capac anticip continu mix currenc neutral organ growth quarter capit equip segment y/i saw declin backlog end quarter record level despit strong shipment consum servic revenu segment oper incom mln om vs mix organ currenc neutral basi strong growth continu core medic devic custom segment oper profit increas mln om vs y/i plc
steri corpor develop manufactur market infect prevent contamin control microbi reduct surgic
support product servic healthcar pharmaceut scientif research industri government custom world-wide
movement toward dispos surgic tool decreas need steril med-tech compani bring high-margin
single-us devic marketplac trend obvious reduc need steril surgic procedur
growth driver outsid may take longer expect materi capit spend may take longer rebound expect
tangibl sign capit equip market due rebound meaning delay could impact capit equip
sale estim compani
compani abil gener sustain earn dividend growth depend upon achiev mid-singl digit revenu growth
number factor impact includ limit price pressur macroeconomic-driven chang patient volum
chang capit purchas budget cycl
